



# ALLOCYTE™

Advanced Cellular Bone Matrix

*A next generation cellular bone matrix.*

- **ALLOCYTE™ Advanced Cellular Bone Matrix** is a next generation cellular bone matrix (CBM) containing bone-derived progenitor cells and conformable bone fibers.
- **ALLOCYTE™** contains all three elements needed for bone formation.
- **ALLOCYTE™** is regulated by the FDA as a Human Cells, Tissues and Cellular and Tissue-Based product (HCT/P) under 21 CFR Part: 1271.



## Osteoconductivity

Cortical bone fibers and cancellous bone particulate provides an environment promoting cell attachment, proliferation, and tissue growth.




## Osteoinductivity

Cortical fibers have undergone a demineralization process to increase osteoinductive potential.



## Osteogenicity

Mineralized cancellous bone contains attached progenitor and bone cells. Cells are not only endured to be viable, but also are measured for activity utilizing MTS assay.



Cell viability after one year of storage is

# 99.55%

of initial Viable & Active cell count.

In vitro, **ALLOCYTE™** showed over

# 6x HIGHER OSTEOINDUCTIVE POTENTIAL

than donor matched control.<sup>2</sup>

## Distinguishing Features

### Handling:

- Bone fibers provide robust and conformable handling.
- Packaged in an open bore syringe to allow delivery directly from syringe.

### Viability:

- Cryopreserved using a DMSO-free cryoprotectant, eliminating the need to rinse and decant the tissue prior to implantation.

### Growth Factor Preservation:

- ALLOCYTE™ undergoes a novel patented process that preserves the native growth factors from ancillary bone lining cells which are typically removed during traditional CBM processing.




Graft viability post thaw

**5 hours**

Thawed in warm saline without decanting in

**10 minutes**

## The Proprietary Processing in Allocyte Preserves Native Growth Factors<sup>1</sup>



- **ALLOCYTE™** undergoes a novel process to remove red blood cells, white blood cells, and adipocytes. Bone progenitor cells remain attached to the tissue and are retained in the implant through implantation.
- Cell count is performed using a functional assay that not only determines viability of the cells, but also ensures the cells exhibit activity via MTS assay. This increased scrutiny **eliminates false positives and inaccurate cell counts.**
- **ALLOCYTE'S™** proprietary process results in removal of immunogenic components mitigating concerns for immune response.



**ALOCYTE™**

Advanced Cellular Bone Matrix



For more information or to place an order,

**call 800.205.7719**

1. Data on file 2. Data on file

ALOCYTE is a trademark of Scendia Biologics

Please refer to the Instructions for Use for description, indications, contraindications, warning, precautions, and other important information.

© 2021 Sanara MedTech Inc. All rights reserved. MKT.06.04 Rev. 220114

Product Code	Product Description	Size
ACBM-010	ALOCYTE™ Advanced Cellular Bone Matrix	1.0cc
ACBM-020	ALOCYTE™ Advanced Cellular Bone Matrix	2.0cc
ACBM-050	ALOCYTE™ Advanced Cellular Bone Matrix	5.0cc
ACBM-100	ALOCYTE™ Advanced Cellular Bone Matrix	10.0cc
ACBM-150	ALOCYTE™ Advanced Cellular Bone Matrix	15.0cc